Pharma Exclusives Pressreleases
Immunovia’s CLARITI study results selected for prestigious presentation at the world’s largest gastroenterology conference
Monday, March 03, 2025Immunovia the pancreatic cancer diagnostics company today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week DDW conference
Teva and Medincell Confirm FDA Review of Application for UZEDY® Extended-Release Injectable Suspension to Treat Bipolar I Disorder
Wednesday, February 26, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Medincell Euronext MEDCL announced today that the supplemental New Drug Application sNDA for UZEDY extendedrelease injectable suspension for the maintena...
Dubai Miracle Garden Blooms with Hope as Boehringer Ingelheim Concludes Interstitial Lung Disease Awareness Campaign
Tuesday, February 25, 2025Boehringer Ingelheim a leading researchdriven biopharmaceutical company has collaborated with Emirates Thoracic Society ETS and social media influencer Ghaith Marwan to raise awareness of Interstitial Lung Disease ILD through a community engagement i...
The European Medicines Agency (EMA) has approved a new subcutaneous administration option for TAKHZYRO® (lanadelumab) to treat hereditary angioedema (HAE) in patients aged 12 years and above.
Monday, February 24, 2025Takedaannounced today that the EMA has approved an additional mL prefilled pen option for TAKHZYRO lanadelumab for subcutaneous administration in adolescents aged years and above and adult patients with hereditary angioedema
Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection against H5 avian influenza
Monday, February 24, 2025VAXXITEK HVTIBDH Boehringer Ingelheim is expanding its proven VAXXITEK range with a new vaccine that protects against three severe poultry diseases Mareks disease Infectious Bursal Disease and H avian influenza Leveraging our extensive expertise in a...
BioMed X Launches New Institute in Barbados
Thursday, February 20, 2025BioMed X Institute is proud to announce a partnership with the Government of Barbados focused on advancing the treatment of cardiometabolic diseases in individuals of African descent This initiative supported by the European Commissions PharmaNext pr...
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy
Wednesday, February 19, 2025AskBio Inca gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG today announced that investigational gene therapy AB for the treatment of Parkinsons disease PD has been granted Regenerative Medicine
Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab
Wednesday, February 19, 2025Celonic Group a Pure Play biologics contract development and manufacturing organization CDMO announced today the signing of a multiyear commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for Commercial Supply
Boehringer's zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Wednesday, February 19, 2025Boehringer Ingelheim today announced that the US Food and Drug Administration FDA has granted Priority Review to its new drug application for zongertinib BI for the treatment of adult patients with unresectable or metastatic nonsmall cell lung cance...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Tuesday, February 18, 2025Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd
